Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
Merck Enters Into Exclusive Global License Agreement With Hansoh Pharma For HS-10535
(RTTNews) - Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize ...
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.
Merck enters obesity drug race in pact with Chinese pharma Hansoh
Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on ...
Futures move higher in run-up to Fed rate decision
U.S. stock index futures edged up on Wednesday, as markets eagerly awaited the Federal Reserve's final rate decision of the ...
lifesciencesweden.se16m
MSD discontinues development of cancer drugs after trial failures
American Merck & Co, known in Europe as MSD, has discontinued the development of vibostolimab and favezelimab, two ...
devdiscourse29m
Global Health Advancements: Eli Lilly's Alzheimer's Treatment Gains Ground
The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...